web analytics
-0.8 C
Munich
Saturday, November 26, 2022

What Happened to AMARANTUS BIOSCI INC(OTCMKTS:AMBS)

AMARANTUS BIOSCI INC(OTCMKTS:AMBS) has continued to make higher highs and higher lows in recent weeks since reversing off $0.21 lows. The reversal is significant as the stock was in significant decline for many months helped along by a 1 for 150 reverse split on June 10, 2015.

AMBS jumped to the top of many speculators watch lists last year after Amgen Co-Founder Joseph Rubinfeld, PhD had joined AMBS Corporate Advisory Board. I believe in MANF,” said Dr. Rubinfeld, “I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen”

AMARANTUS BIOSCI INC(OTCMKTS:AMBS) is developing LymPro, a blood test for the diagnosis of Alzheimer’s disease. Clearly there is a significant market demand for a product like LymPro that can quickly distinguish between patients with Alzheimer’s and other degenerative dementias such as Parkinson’s disease. dementia or old age-related memory loss.

Currently testing for Alzheimer’s is a lengthy, expensive and complicated process and with an overwhelming number of researchers and publications pointing to early diagnosis as critical to extending a patient’s quality of life the demand for a product such as LymPro grows.

Amarantus Bioscience Holdings is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. AMBS has licensed Eltoprazine, a Phase 2b-ready small molecule drug indicated for Parkinson’s Levodopa induced dyskinesia and adult ADHD.

AMBS also has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test®) for Alzheimer’s disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF). Amarantus is developing MANF-based products as treatments for orphan ophthalmological disorders and other indications.

As well AMBS owns intellectual property for the diagnosis of Parkinson’s disease (NuroPro) and the discovery of neurotrophic factors (PhenoGuard). Amarantus operations are located in offices and labs at Janssen Labs.

MANF is a protein that corrects protein misfolding. Protein misfolding is one of the major causes of apoptosis (cell death). This property provides a compelling rationale for the research and development of MANF-based products as therapeutics for human disease. Our lead MANF product development effort is centered on a therapy for Parkinson’s disease.

Back in 2012 the Company entered into an exclusive worldwide license agreement with the University of Massachusetts Medical School for intellectual property surrounding the use of mesencephalic astrocyte-derived neurotrophic factor (MANF) as both a biomarker and a treatment for beta cell-degenerating disorders (the “License”).

For more info on AMBS Please Subscribe below, also you should know we have Something Huge Coming!

The license agreement includes all intellectual property covering the use of MANF as a biomarker and treatment for beta cell degeneration disorders, including Wolfram syndrome, Type-1 diabetes and Type-2 diabetes. The License expands the company’s extensive intellectual property portfolio for MANF, including composition of matter and method of use patents and patent applications worldwide for MANF and derivative sequences for protein therapy, gene therapy and cell therapy applications.

On December 22 AMBS announced an update on the status of its current manufacturing process validation for producing ESS at Lonza Walkersville, a premier contract manufacturer providing cell- and tissue-based products for clinical development. Ongoing engineering run activities are progressing successfully, and Amarantus expects to complete the necessary steps to confirm the process in January.

Upon completing the validation studies, Amarantus will be ready from the operational perspective to open the planned Phase 2 clinical study for the treatment of full thickness thermal burns covering over 50% of the body. The trial is being conducted under a Collaborative Research & Development Agreement (CRADA) with the U.S. Army at the Institute for Surgical Research at Fort Sam Houston in Texas.

Milestones towards validation are as follows: Aseptic process simulation execution and qualification of the process and personnel used in manufacturing: Completed in November 2015. Initial engineering run whereby autologous full thickness skin from an adult human donor is produced: Completed in December 2015. Confirmatory engineering run whereby autologous full thickness skin from an adult human donor is produced: In progress – Expected completion in January 2016.

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $7.8 million market valuation AMBS has minimal assets, rising short term debt and no revenues to date. But this is an exciting story developing in small caps; AMBS is a biotechnology company developing therapeutic and diagnostic product candidates based on the MANF protein with several new drugs under development and currently trades at the lowest market valuation this Company has seen in years. We will be updating AMBS as events unfold so make sure you are subscribed to Microcapdaily so you know what is going on with AMBS.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in AMBS either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.